Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | BCL9 | O00512 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9066838 | 0.89 | PTGS2 (0.54) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL17562364 | 0.86 | PTGS2 (0.51) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL2961207 | 0.86 | PTGS2 (0.51) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL13962353 | 0.86 | PTGS2 (0.51) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL4743797 | 0.85 | LMNA (0.53) | PTGS2ALDH1A1MAPTLMNAMAOB | |
| SCHEMBL4356670 | 0.84 | KCNH2 (0.51) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL10452633 | 0.83 | PTGS2 (0.49) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL31177588 | 0.83 | PTGS2 (0.49) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL10452634 | 0.82 | PTGS2 (0.55) | PTGS2ALDH1A1MAPTCYP3A4LMNA | |
| SCHEMBL2561735 | 0.82 | MAPT (0.54) | PTGS2ALDH1A1MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080098-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-3080098-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-9802920-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMAN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802920-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMAN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802920-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMAN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-20 | — | — | US | disclosed |
| EP-3080098-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086636-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
| EP-0273242-A2 | 2-Pyri(mi)dylthio-aryl ether | BAYER AG (DE) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | PTGS2 20/4885ALDH1A1 875/4885MAPT 2366/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | PTGS2 157/4885ALDH1A1 3986/4885MAPT 4336/4885 |
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | PTGS2 2191/4885ALDH1A1 3931/4885MAPT 3742/4885 |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | CSGALNACT1, ST3GAL3, FUT6 | PTGS2 1607/4885ALDH1A1 936/4885MAPT 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.